

2024 Investor Day

Transforming Agriculture, Delivering Value

November 19 | New York City



Welcome and Opening Remarks



Kim Booth | VP, Investor Relations



Today's Agenda

9:00 AM Welcome and Opening Remarks Kim Booth | VP, Investor Relations

Corteva Strategy and Performance Outlook

Chuck Magro | Chief Executive Officer

The Future of Agriculture Brook Cunningham | SVP, Chief Strategy Officer

Growth through Innovation

Sam Eathington | EVP, Chief Technology and Digital Officer

10:15 AM Q&A Session

10:35 AM Break



10:45 AM Seed Business Overview Tim Glenn | EVP, Seed Business Unit

Crop Protection Business Overview

Robert King | EVP, Crop Protection Business Unit

Positioned for Success Panel Discussion

Moderator: Dave Anderson | Special Advisor to the CEO Panelist: Tim Glenn | EVP, Seed Business Unit Panelist: Robert King | EVP, Crop Protection Business Unit

Financial Framework David Johnson | EVP, Chief Financial Officer

Closing Remarks Chuck Magro | Chief Executive Officer

12:00 PM Q&A Session



Safe Harbor Regarding Forward-looking Statements

Forward-looking Statements

This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates," "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; environmental, sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition. Some of the important factors that could cause Corteva's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva's products; (ii) failure to successfully develop and commercialize Corteva's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) costs of complying with evolving regulatory reguirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vi) effect of climate change and unpredictable seasonal and weather factors; (vii) failure to comply with competition and antitrust laws; (viii) effect of competition in Corteva's industry; (ix) competitor's establishment of an intermediary platform for distribution of Corteva's products; (x) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xi) effect of volatility in Corteva's input costs; (xii) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the separation of Corteva; (xiv) risks related to Corteva's global operations; (xv) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xvi) effect of industrial espionage and other disruptions to Corteva's supply chain, information technology or network systems; (xvii) failure of Corteva's customers to pay their debts to Corteva, including customer financing programs; (xviii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xix) increases in pension and other post-employment benefit plan funding obligations; (xx) capital markets sentiment towards sustainability matters; (xxi) risks related to pandemics or epidemics; (xxii) Corteva's intellectual property rights or defense against intellectual property claims asserted by others; (xxiii) effect of counterfeit products; (xxiv) Corteva's dependence on intellectual property cross-license agreements; and (xxv) other risks related to the Separation from DowDuPont.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.

Financial forecasts, including 2024 and 2025 guidance and mid-term targets, do not contemplate any extreme weather events, operational disruptions, significant changes in customers' demand or ability to pay, further acceleration of currency and inflation impacts resulting from macro-economic driven trends, any escalation of military conflicts, or any material change in the socio-political environment.



Reminder About Non-GAAP Statements

Regulation G (Non-GAAP Financial Measures)

This presentation includes information that does not conform to U.S. Generally Accepted Accounting Principles ("GAAP") and are considered non-GAAP measures. These measures include operating EBITDA, operating EBITDA margin, operating earnings (loss) per share, Free Cash Flow, Free Cash Flow Conversion, and Average Free Cash Flow Conversion. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results.

These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies Reconciliations for these non-GAAP measures to U.S. GAAP are provided at the end of this presentation.

The Company is not able to reconcile its forward-looking non-GAAP financial measures, except for Free Cash Flow, to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as significant items, without unreasonable effort. For significant items reported in the periods presented, refer to the non-GAAP reconciliations at the end of this presentation. Beginning January 1, 2020, the Company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the noncash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. Due to the ramp-up of Enlist E3®, Corteva significantly reduced the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait thereafter. In 2023 and 2024, the Company committed to restructuring activities to optimize its Crop Protection network of manufacturing and external partners, which are expected to be substantially complete in 2026. The Company expects to record aggregate pre-tax restructuring and asset related charges of \$650 million to \$700 million for these activities.

Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating benefits (costs), tax indemnification adjustments, environmental remediation and legal costs associated with legacy businesses and sites and the 2021 officer indemnification payment. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense. Operating EBITDA margin is defined as Operating EBITDA as a percentage of net sales. Operating earnings (loss) per share is defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of non-operating benefits (costs), the after-tax impact of anortization expense associated with intangible assets existing as of the Separation from DowDuPont and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Altonot painties assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Altonot intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instrume

The Company also uses Free Cash Flow, Free Cash Flow Conversion, and Average Free Cash Flow Conversion as non-GAAP measures to evaluate and discuss its liquidity position and ability to generate cash. Free Cash Flow is defined as cash provided by (used for) operating activities – continuing operations, less capital expenditures. Free Cash Flow Conversion is defined as Free Cash Flow divided by Operating EBITDA. Management believes that Free Cash Flow Conversion and Average Free Cash Flow Conversion provide investors with meaningful information regarding the Company's ongoing ability to generate cash through core operations, and the Company's ability to service its indebtedness, pay dividends (when declared), make share repurchases, and meet its ongoing cash needs for its operations. Corteva is not able to reconcile its forward-looking Free Cash Flow Conversion and Average Free Cash Flow Conversion non-GAAP financial measures to their most comparable U.S. GAAP financial measure, as it is unable to predict with reasonable certainty Operating EBITDA due to items outside of the Company's control, which include the same Significant Items noted above, without unreasonable effort.

Five-year performance data, non-GAAP metrics and reconciliations can be found on the Company's investor relations page, https://investors.corteva.com/financial-information/quarterly-earnings-reports.



Corteva Strategy and Performance Outlook




Chuck Magro | Chief Executive Officer





Corteva Snapshot (NYSE: CTVA)



Pure-Play AgTech Company, Helping Farmers Feed a Growing Population



Ag Technology is Critical to Solving Some of the World's Biggest Challenges

Food Security	Climate Change	Energy Transition
Growing population with ~2B more people in the next 25 years ¹	10 – 25% potential reduction in crop yields in key regions from 2°C increase in global temperatures ²	Demand for NextGen Biofuels in North America and Europe expected to reach 22B gallons by 2040 ⁴
	Up to 40% of crop production globally lost to pests ³	
Need to feed more people	Food is getting harder to grow	Governments incentivizing, mandating biofuel use
10.8 m		
Andre Alexandre		
CORTEVA arriscience ¹ United Nations, Department of Economic and ² Jägermeyr, J., Müller, C., Ruane, A.C. et al. Clim technology changes or improvements.	Social Affairs, Population Division (2024), World Population Prospects 2024, Online Edition, ate impacts on global agriculture emerge earlier in new generation of climate and crop model	s. Nat Food 2, 873–885 (2021); assumes no 2024 INVESTOR DAY 8

Performance Since 2022 Investor Day

WHAT WE SAID AT 2022 INVESTOR DAY 2025 Targets

100 – 150 bps margin² improvement per year

Reduce net royalties by ${\bf 50\%}$ – clear path to royalty neutrality by end of decade

+60% of Crop Protection revenue from differentiated products and exit ~5% of revenue (~20% of active ingredients) to focus on core markets and crops

reconciliations at the end of this presentation.

~60% of Enlist E3^{®1} on U.S. soybean acres

Targeting **\$4.1 – \$4.7B** operating EBITDA²

WHERE WE ARE TODAY 2025 Guidance

320 bps margin² improvement since YE2022

Net royalty reduction of **~70%** and on track for royalty neutrality by end of decade (~1 year early)

~65% of 2025 Crop Protection revenue from differentiated products, executed Biologicals acquisitions, completed
 ~\$500M of low-margin product exits

Enlist E3^{®1} on ~65% of U.S. soybean acres

Estimating **\$3.6B – \$4.0B** operating EBITDA² (Seed on plan, Crop Protection lowered due to market dynamics)

Delivering Strong Profitability and Cost Management through More Challenging Environment



¹ The transgenic soybean event in Enlist E3[®] soybeans is jointly developed and owned by Corteva Agriscience and M.S.
 ² Operating EBITDA and Operating EBITDA margin are non-GAAP measures. See slide 5 for further discussion and

Exceeded Goal

2024 INVESTOR DAY 9

Revised Goal

Exceptional Track Record as a Public Company

500bps+

Operating EBITDA Margin¹ Improvement²

from Controllable Levers

Including Productivity

\$6B+ Cumulative R&D Investments Since 2019

2K+

New Seed and Crop Protection Products², Backed by 7K+ Patents

\$1.3B Cumulative Benefits³

and Royalties

~\$4.8B

Cash Returned to Shareholders 2019 – 2023

\$1.3B+

Annual Operating EBITDA¹ Improvement² (10% CAGR)

Strong Financial Performance Backed by Breakthrough Innovation



FIVE YEARS

GROWING

¹ Operating EBITDA and Operating EBITDA margin are non-GAAP measures. See slide 5 for further discussion and reconciliations at the end of this presentation.
 ² Growth amounts reflect data from the period January 1, 2019 – December 31, 2023; comparative financial periods use data for the year ended December 31, 2018 as a base.
 ³ FY2021 through FY2023.

What Sets Corteva Apart

Best-in-Class Germplasm

Continuous corn breeding has developed most evolved germplasm pool



IP Portfolio and Pipeline Regulatory expertise, patents, and active ingredients

Pioneer[®] Brand Loyalty High-touch experience with premium products and services

Advantaged Route-to-Market

Premium customer experience meets the evolving needs of the farmer

Growth Platforms Seed and Trait Out-Licensing, Biologicals, Crop Protection New Products, Gene Editing, Biofuels, and Hybrid Wheat

Global Supply Chain and Local Production Capabilities Production, manufacturing, and R&D facilities



Competitive Advantages Enable Long-term Growth



Integrated Platform Drives Differentiation

SEED

Best-in-Class Germplasm Biotech Expertise Pioneer[®] Brand Loyalty Advantaged Route-to-Market Strategy Robust Patent Portfolio **CROP PROTECTION**

Discovery and Commercialization Regulatory Expertise Biologicals Scale and Capabilities Product Differentiation Manufacturing and Cost Excellence

Gene Editing

Seed Applied Technologies


Decision Science



Common Customer Base + Single Innovation Engine + Advantaged Routes-to-Market



Growth Platforms – Ability to Sustain Long-Term Growth



Clear Path to Near-Term Growth Acceleration



\$4B+ Addressable Out-Licensing Market¹

Royalty Neutrality by End of Decade

Growth through Licensees and Multipliers



Market-Leading, Global Position

Targeting **\$1B** in Biologicals Revenue by End of Decade

Robust, Complementary Biocontrol Pipeline



~**\$550M** of Additional Revenue by 2027

Delivering Differentiated, Farmer-Centric Offerings

Ongoing Ramp-up of Adavelt[™] and Reklemel[™]

Anticipating \$1 Billion in Incremental Revenue by 2027



Investing in Long-Term, Multi-Year Growth Platforms




1,400+ Unique Gene Targets Edited, **300**+ Edits Field Tested

The Future of Plant Breeding and Product Development

USDA-APHIS Regulatory Authorization for Corn MDR¹

¹ Multi-disease resistance corn.



Delivering Value in Frontier Double Cropping System

Demand for NextGen Biofuels Expected to Reach ~10B Gallons by 2030²

100M+ of Potential Global Acres for Double Cropping Systems³



Driven by New Proprietary Sterility System

10% Yield Advantage Potential, with Up to **20%** Under Stress⁴


~**550M** Acres of Wheat Planted Globally Each Year⁵

Unlocking Multi-Billion Dollar Revenue Opportunities in Next Decade



^a ² IEA (2024), Renewables 2024, IEA, Paris.
 ^a Corteva Internal Analysis.
 ⁴ Internal yield trial testing; 2 years of testing with 6-10 locations/year in each of the market classes. HRW testing in NE, KS, CO, OK.
 ⁵ FAO, Global wheat area harvested in 2022.

2025 – 2027 Scorecard for Success



Accelerating Execution to Achieve Long-term Value Creation



Why Invest in Corteva?

01

02

03

Strong competitive advantages and deep proprietary expertise, to address one of the world's most essential needs **Proven value creator**, with track record of improving profitability and returning capital to shareholders

Significant growth potential,

driven by product innovation and proven ability to capture share



The Future of Agriculture

Positioned for Ongoing Leadership in a Critical and Growing Industry



Brook Cunningham | SVP, Chief Strategy Officer



Key Messages



Leading the way in a **critical global industry** addressing significant food and energy needs



Demands on agriculture continue to increase while crops are getting harder to grow



Farmers need **breakthrough technologies and differentiated solutions** to rise to global challenges, sustainably



Seed and Crop Protection industries will remain essential, **well-positioned** for attractive long-term growth





Agriculture is a Critical, Growing Global Industry...



...and Will be Even More Critical in Years to Come



Sources: FAO (2024) Gross domestic product and agriculture value added 2013–2022 – Global and regional trends. FAOSTAT Analytical Briefs, No. 85. Rome. FAO (2024) Forest and Farm Facility – Family Farmers' campaign.

Intensifying Global Demand for Food and Fuel

Demand Tailwinds		
Population Growth	Rise of Biofuels	
+10% Global Population Growth Over Last Decade with Another 18% Growth Expected by 2050 ¹	+9% Global Crude Oil Consumption Growth Over Last Decade ²	

+27%

Global Income Growth Over Last Decade³ Driving Increased Demand for Higher Quality of Food

8x

Increase in Gallons of Renewable Diesel and SAF⁴ Needed to Meet Demand by 2050⁵



Population & Income Growth and Rise of Biofuels Drive Sustained Industry Tailwinds



¹ United Nations, Department of Economic and Social Affairs, Population Division (2024). World Population Prospects 2024, Online Edition.
 ² U.S. Department of Energy-Energy Information Administration.
 ³ International Monetary Fund, DataMapper Tool (2024).

2024 INVESTOR DAY 21

⁴ Sustainable Aviation Fuel.
⁵ S&P Global Commodity Insights. Fueling the Future – Biofuels driving progress on net zero (February 2024); Corteva Internal Analysis.

NextGen Biofuels Create Potential Step-Change in Demand for Crops

Technology Will be Critical to Scaling Sustainably

NextGen Global Biofuel Consumption (Billion Gallons) 50 40 **8**x 30 4.5x 20 10 2020 2026 2024 2025 2028 2029 2030 2040 2050 2021 2022 2027 2023 Renewable Diesel SAF

Demand for Renewable Diesel and SAF would require production to double by 2030 and grow more than 8x by 2050

 Combined, North America and Europe are expected to reach demand of 22B gallons by 2040 and 30B gallons by 2050

SAF will drive growth as the primary way to decarbonize aviation by 2050

- Global demand forecast estimated at ~32B gallons
- In the EU alone, jet fuel blend requirement expected to reach 70%


Scaling of new double cropping systems will be required to meet demand

- Over 100M acres could be available for the development of double cropping systems, globally
- Allow farmers to optimize year-round land usage and increase revenue

Multi-Billion Dollar Incremental Revenue Opportunity for Agriculture by End of Next Decade



Farmers are Being Asked to Produce More with Less: Crops are Getting Harder to Grow



Supply Pressures Finite Availability of Climate Changes and More Stringent Arable Farmland Rising Pest Pressure Regulations 30% 10 – 25% ~16 Years of Land Has Been Lost **Potential Reduction in** and ~\$115M to Bring to Urbanization and **Crop Yields in Key** New Seed Biotech Trait Soil Degradation Over **Regions** from 2°C Increase to Market Last 40 Years¹ in Global Temperatures² 70% **Up to 40%** 12+ Years of Crop Production of Global Population and \$300M+ to Bring Will Be in Urban Areas **Globally Lost** to Pests⁴ a New Crop Protection

Continued Delivery of New Innovation to Farmers will be Critical to Their Success



¹ Cameron, D., Osborne, C., Horton, P., & Sinclair, M. (2015). A sustainable model for intensive agriculture. Grantham Centre for Sustainable Futures, University of Sheffield. Retrieved from Grantham Centre briefing note: December 2015.

by 2050, Further Straining

2 Jägermeyr, J., Müller, C., Ruane, A.C. et al. Climate impacts on global agriculture emerge earlier in new generation of climate and crop models. Nat Food 2, 873–885 (2021); assumes no technology changes or improvements.

Agricultural Land³

2024 INVESTOR DAY 23

Molecule to Market

³ United Nations, Department of Economic and Social Affairs, Population Division. (2018, May 16). 2018 Revision of World Urbanization Prospects. United Nations. ⁴ Food and Agriculture Organization of the United Nations. (2021, June 2). Climate change fans spread of pests and threatens plants and crops, new FAO study.

Broad Range of Critical Technology Tools and Solutions Required to Address Farmer Needs




Helping Farmers Overcome Challenges, Drive Productivity to Meet Global Demand



Technology is Essential to Enabling Productivity and Minimizing Resource Utilization

Global Average Yield (MT/HA)


Aggregate of 14 Crops¹



35% Increase in Global Average Yield Over Last 25 Years

Area Used to Supply Global Demand

What Would Have Been Needed at 2000 Yield Level (Mil HA)²




Crop Technology has Enhanced Productivity and has Prevented 500 Million Acres from Entering Production

Source: USDA, Corteva Internal Analysis.

* ¹ Yields per hectare for an aggregate of 9 grains (corn, wheat, rice, sorghum, barley, oats, rye, millet and mixed grains) and 5 oilseeds (soybeans, rapeseed, sunflower seed, peanuts and 2024 INVESTOR DAY 25 cottonseed).

² Aggregate of 9 grains (corn, wheat, rice, sorghum, barley, oats, rye, millet and mixed grains) and 5 oilseeds (soybeans, rapeseed, sunflower seed, peanuts and cottonseed).

Market Outlook Stabilizing into Normal Range



Farmers Prioritize Yield and Productivity as Income Levels Normalize



Source: Corteva internal calculations based on historical source data from USDA ¹ Most likely range represents internal estimates for U.S. only.


Most Likely Range¹

Europe

U.S.

Brazil 2024 IN

Farmers Prioritize Seed and Crop Protection Investments Over Others



When commodity prices drop, farmers move to protect margins by prioritizing productivity

Seed and Crop Protection spend remains resilient through high and low farm income environments

Core fundamental truths:

Farmland will continue to be planted


 Farmers will defend their crops against pests and disease

 Advanced tech will be critical as food becomes harder to grow

Seed and Crop Protection Sales: Resilient through the Cycle



Seed and Crop Protection Sectors Well-Positioned for Attractive, Sustained Growth



Corteva Presents a Compelling Opportunity in a Critical, Growing Global Industry



Source: Corteva Internal Analysis.
 ¹Crop Protection market based on manufacture level. Crop Protection Traditional includes fungicides, insecticides, and selective herbicides; excludes glyphosate. Seed market based on grower-level value including branded business and out-licensing revenue; excludes China.
 ²Seed applied technology.

Key Takeaways

Leading the way in a **critical global industry** addressing significant food and energy needs **Demands on agriculture** continue to increase while crops are getting harder to grow Farmers need breakthrough technologies and differentiated solutions to rise to global challenges, sustainably Seed and Crop Protection industries will remain essential, well-positioned for attractive long-term growth



Growth through Innovation



Sam Eathington, Ph.D. | EVP, Chief Technology and Digital Officer



Key Messages



Proven value creator over the last 5 years



Delivering near-term growth in our Seed and Crop Protection portfolios



Fueling the future of agriculture and Corteva


- Expanding our seed leadership through proprietary technology, new agricultural systems, and gene editing
- Complementing **differentiated** Crop Protection excellence with **leadership position in biologicals** and **natural products**
- Maximizing product performance and sales enablement with **decision science**





Proven Value Creation – Five Years of Corteva Highlights *Proven Track Record of R&D Excellence*





Created and funded **Corteva Catalyst^{TM10}** with **6** deals closed across four strategic verticals


100% of Solutions Meet Our Sustainable Innovation Criteria Across Our \$24B' R&D Pipeline



¹ Corteva has launched, on average, 300+ seed products/year for the past 5 years.
 ² Biotech trait packages launched: 6 corn, 3 soybean, 2 canola, 1 cotton
 ³ Data are based on average of 2024 comparisons with competitors (+/- 3 CRM) through Oct. 28, 2024
 ⁴ Corteva has launched, on average, 150+ crop protection products/year over the past 5 years. These include products based on the 3 new active ingredients.

⁵ Utrisha-N is registered in 50+ countries on a wide range of crops including row, horticultural, and specialty crops.
 ⁶ Similar to pharmaceutical observations, our Biotech trait discovery timelines have moved from years to months.
 ⁷ Corteva has achieved 1200+ global regulatory approvals supporting new crop protection product launches/uses and seed cultivation/import.
 ⁸ Data from Corteva internal IP management system
 ⁹ Calculation as of 2023
 10 Corteva Agriscience's investment and collaboration platform

Growth Drivers for Near-Term Value





Annual yield improvements, net royalty expense reduction, and new business opportunities Differentiated Crop Protection


NEW ACTIVES & FORMULATIONS

Solving evolving farmer challenges and protecting yield with synthetic and biological products

Foundations of Corteva Innovation and Value Creation



Advantaged Germplasm Creates New Value Every Year



Proven Value Creator – Strongest Performing Lineup in 25 years



¹ World Records for corn and soybean observed and reported through third party yield contests.
 ² Data are based on average of Pioneer* 2024 hybrid comparisons with competitors (+/- 3 CRM) through Oct. 28, 2024.
 ³ In areas of medium to high tar spot pressure (25,700+ comparisons at over 500 locations), Pioneer family hybrids out yield competitive alternatives (+/- 3 CRM).
 ⁴ Data are based on average of Pioneer * 2024 E3 Z-Series variety comparisons (3,700+ comparisons), Pioneer family hybrids out yield competitive alternatives (+/- 3 CRM).
 ⁵ Based on Corteva Internal Analysis and reported USDA acres as of June 30, 2024.
 ⁵ Based on Corteva Internal Analysis and reported USDA acres as of June 30, 2024.
 ⁶ PowerCore*Enlist*, Vorceed* Enlist*, Enlist E3* Soybeans, Z Series Soybeans, and Conkesta E3* Enlist are registered trademarks of Corteva Agriscience[™]. The transgenic event in the Enlist E3® soybeans is jointly developed and owned by Corteva Agriscience and MS. Technologies LLC.

New Actives and Formulations to Protect Yield




Proven Value Creator – Differentiated Solutions to Protect Yield



 ¹ Crop treated with Salibro™ protected from plant parasitic nematode damage.
 ² A few months after an application of new NovaGraz™ herbicide near Sleeper, Missouri, the treated photo contains a desirable mix of grass, white clover and annual lespedeza. Broadleaf weeds dominate the untreated photo.

Key Drivers of Additional Future Value




Proprietary Technology

Continuing our journey of expanding proprietary traits and building on our crop protection leadership




Building on Record Corn Performance with NextGen Proprietary Traits



Solving Problems for Farmers and Delivering New Business Opportunities




Building on Record Soybean Performance with NextGen Proprietary Traits



Delivering New Solutions for Farmers and Expanding Business in the Americas



New Crop Protection Products with Proprietary Actives and Formulations



Addressing Insect, Weed, and Disease Pressures with Differentiated Solutions



Note: Launch timelines pending applicable global regulatory review.

¹ Market leading efficacy against whitefly, brown planthopper, and spittlebug.

² Addresses Lepidopteran and Beetle chewing segment.

³ SAT = Seed Applied Technologies. Strengthens ownership of MoA Group 5 with differential segmentation.


New Agricultural Systems

Market expanding technologies unlocking productivity and sustainable agriculture



2

Hybrid Wheat – A New Revolution in Agriculture



Launching 2027 in Hard Red Winter Wheat – Disruptive Innovation for ~550M⁴ Acres



Note: Launch timelines pending applicable global regulatory review; Corteva plans to launch hybrid Hard Red Winter wheat as early as 2027 in North America, adding to its portfolio over time. ¹ Represents mean bushels/acre year gain across 58 years in Kansas for Hard Red Winter Wheat (HRW).

2024 INVESTOR DAY 42

² Represents Corteva conservative estimates based on current breeding program and applying hybridization and advanced breeding tools to HRW. ³ Internal yield trial testing; 2 years of testing with 6-10 locations/year in each of the market classes. HRW testing in NE, KS, CO, OK. ⁴ FAO, Global wheat area harvested in 2022.

Hybrid Wheat – Breakthrough Technology Enables Value Creation

Proprietary Male Sterility System


Corteva's Proprietary Genetic System

- Non-GMO, Non-CMS¹, Non-Chemical
- Stable male sterility in 100% of germplasm and wheat classes tested²
- More effective plant breeding process
- More efficient parent seed production

Hybrid Wheat Production Efficiency

Efficient System is Key to Production Scale

- Performs in **all environments and geographies** tested
- Because system is germplasm independent, opportunity to optimize parental traits for improved seed production
- Delivers **production cost advantage** and allows rapid scale delivery to farmers, creates value on larger number of acres



Platform Enables Continued Productivity Transformation



Corteva Technology Shaping NextGen Global Biofuels

Bunge-Chevron	Leading Corteva Technology	bp
 Field to fuel" program setting new standards for biofuels production Combines entire value chain from field to fuel production 2023 winter canola pilot of 5k commercial acres Excellent yield of 54 bu/acre¹ Potential system opportunity on up to 10 million acres TX expansion in 2024-2025 ~35k acres planted for 2024-2025 	<section-header><section-header><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></section-header></section-header>	 Global EU SAF² feedstock production 1 argeting 1 million metric tonnes of vegetable oil by mid-next decade 2 Leveraging global operations and processing assets 3 Operational 2H 2025 Canola Diraction and Diraction and Diraction and Diraction assets Canola Diraction and Diraction and Diraction and Diraction and Diraction assets Canola Diraction and Diracti

Building on Leadership Position in Canola, Winter Canola, Mustard, and Sunflower



Reduced Stature Corn – Accelerating Yield Improvement

Corteva Advantage

Delivering Resilience and Optionality

- Dominant native gene for reduced stature is the base for a generational product line
- Delivered in our industry-leading, traited germplasm
- Providing consistent plant height reduction and ear height for all growing conditions tested
- Consistency enables over the top equipment application options
- Works with farmers equipment
- Improved standability vs. non-RSC corn



Building on our Advantage

Unlocking Value through Yield Improvement

- Building additional yield on a new stable, lodging resistant foundation
- Higher plant density, to accelerate gains in yield per acre
- Building on reduced stature platform with gene editing to expand potential
- Enhanced by decision science through Granular Insights for field- and hybridspecific seeding and crop protection prescriptions

Yield Increase by Accelerating Adoption of Higher Plant Density



Gene Editing

Industry-leading advanced plant breeding that accelerates yield performance



3

GenlytixTM Ecosystem – Industry-Leading Gene Editing Capabilities *Rapidly Scaling to Accelerate Product Creation*


In-House Leading Gene Editing Technology

- **4** gene editing platforms
- 10 crops edited
- 1,400+ unique gene targets
- Editing in 100% elite corn germplasm

Partnerships Enabling Accelerated Discovery

- Ecosystem of partnerships across 12 universities, 4 food companies, and 8 startups
- 41 CRISPR-Cas9 out-licensing agreements





Delivering Solutions that Drive Productivity

- **350+** gene editing **patents** granted with **300+ edits** field tested
- 140k+ edited plants
- **70+ multiplexed** edits in a single plant

Global Regulatory and Stewardship Efforts

- 9 philanthropic projects across 4 countries
- 2 Corteva-led value chain transparency programs

Game-Changing Multi-Disease Resistance

Corteva's Proprietary Genlytix[™] Platform

- Powering yield protection and resistance to four devastating crop diseases
- Enabling **breeding acceleration**

First Generation Concept Status

- Pursuing **corn and soy** concepts in both NA & LA regions
- Excellent field performance and efficacy in NA corn
- Received USDA regulatory authorization¹

Expanding our Disease Targets


- 6 additional disease targets
- 30+ genes for protecting against resistance and increasing durability

Diseases Causing \$1 Billion² + of Yield Loss in North America Corn – Launching 2028³



¹ Authorized for planting in the United States; USDA confirmed exempt from Part 340 regulation.
 ² \$595M for Grey Leaf Spot, \$210M for Anthracnose leaf blight & stalk rot, \$221M for Southern Rust, \$212M Northern Leaf Blight | Source: CPN Report for US & CA market, years
 2017-2023.
 ³ For North American concept, pending applicable global regulatory reviews and completion of field testing.

Gene Editing Yield – New Phase of Plant Breeding



Potential to Double Rate of Yield Improvement in Elite Germplasm



¹Genetic recombination is the exchange of DNA between parental inbreds which leads to production of offspring with combinations of traits that differ from those found in either

Biologicals

Delivering biological and naturally-inspired products that complement synthetic chemistry



4

Utrisha[®]N: Delivering Significant Yield Increases in Brazil

Crop Health





Untreated

Utrisha®N


Utrisha[®]N

Registered in 50+ countries for use on a wide range¹ of row, specialty, and horticultural crops



Robust Yield Benefits

- Corn average yield increase ~4.4 bu/A
- Soy average yield increase ~2.6 bu/A²



Symborg Technology + Stoller Customer-Centric Sales + Corteva Capabilities



¹ Corn, soybean, potato, wheat, tree nuts, grapes, rice, sugar cane, banana, barley, oat, canola, pasture, sorghum, cotton, lettuce, melon... Soybean – key crop added post merger. 8 new 2024 INVESTOR DAY 51 countries post acquisition. ² 80.5% win-rate in 411 Soybean Trials 2022-2024.

Delivering New Biocontrol Products that Complement Synthetic Chemistry

Leveraging Complementary Chemistry & Biologicals for Insect Control in Tomato




Plant Surface Damage (%) 74 48 Untreated Qalcova 200 ml/ha Qalcova 200 ml/ha

Managing MRLs² and efficacy throughout the growing season


Creating a Microbial Discovery & Development Ecosystem

Building from **small molecule natural products** to **live microbial** technology



Microbial Engineering for NextGen Biological Solutions

Natural Products



- Expertise in metabolic engineering of microbials has increased manufacturing productivity ~ 230%
- Extending seed genetic improvement capabilities to improve efficacy and stability of live microbial products

Genlytix[™] Platform for NextGen Biologicals – Launching Biocontrol 2028



Note: Launch timelines pending applicable global regulatory review. ¹ Data represents 2024 trials conducted in Murcia, Spain. ² Maximum Residue Limit.

Decision Science

Artificial intelligence and digital tools accelerate R&D innovation and enable farmers to maximize product performance



5

Accelerating R&D with Artificial Intelligence¹

Biotech Proteins

~12X increase from traditional to AI-driven discovery

Biologicals

~1,000X increase in speed of identifying molecular structures

Microbial Metabolites

~7X increase in structural prediction accuracy

Field Performance 80M+ observations using our imaging drone fleet

Small Molecule Discovery 10⁵² expansion of chemical search space

Regulatory Submissions

100X+ increase in development of non-technical documents

The ability to **broaden** our search space and find novel, higher-value discoveries at a faster pace is enabling us to strengthen our early pipeline across both seed and crop protection

Enabling Transformative Discovery at Unprecedented Speed



Reinvented Granular Insights as Data-Driven Sales Tool, Powered by Artificial Intelligence



Further Differentiate Our Products and Pioneer Sales Representatives



¹ Out of ~1200 pairwise hybrid combinations tested on 30 (or more) locations each, the seed placement model was able to predict the winning hybrid with ~74% accuracy and deliver an average +4.5 bu/ac yield advantage.
 ² 297 trials conducted between 2020 and 2023 representing Corteva timing predictions vs Grower timing or untreated control.

Key Takeaways

01	02	03	04	05
Track record of proven value creation that continues to drive our near- term growth	Building on a foundation of world-class germplasm and crop protection molecules	We stand alone in our scale, technology, and focus as we fuel the future of agriculture	Delivering a growing pipeline of proprietary technology accelerated by decision science capabilities	Powering disruption with new cropping systems and clear leadership in gene editing and biologicals

Seed Business Overview

Global Leader with Innovative Solutions and Differentiated Customer Experience



Tim Glenn | EVP, Seed Business Unit



Key Messages



Leading the corn and soybean markets globally with a clear profitable growth strategy



Innovating for the future to drive product excellence, productivity, and value for farmers



Delivering a differentiated customer experience with a focused brand strategy across advantaged routes-to-market



Expanding EBITDA margins through proprietary technology, industry-leading brands, and execution excellence






Seed Snapshot

Financial Performance


aariscience



Significant Accomplishments Since 2022 Investor Day

- ✓ Market share growth in key markets and brands
- Implemented price-for-value strategy in multiple routes-to-market
- Advanced traits and technology in **best-in-class germplasm** delivering world record yields in corn and soybean
- ✓ Cost and productivity gains through continuous improvements and strong execution

CORTEVA^{**} ¹ Market rank based on branded business. Source: Agrowin 3rd-party market research. ² Excluding China.



Attractive and Growing Addressable Seed Market¹

Significant Upside Opportunity Driven by Long-Term Agricultural Trends

~\$67B Global Seed Market

~\$38B Corteva Addressable Seed Market

2024

~**\$90B** Global Seed Market

~\$50B
Corteva Addressable
Seed Market

2035E



¹ Market based on grower-level value including branded business and out-licensing revenue; excluding China. Source: Corteva Internal Analysis. Proactively positioning for attractive industry trends to drive above market growth

- Food security for a growing population
- Increasing adoption rates of technology and automation
- Customer focus on balancing profitability and sustainability

Long-Term Strategy to Drive Growth and Stronger Margins

Unlock Customer Value with Proprietary Technology Enable a Differentiated Customer Experience through Industry-Leading Brand Portfolio

Create Long-Term Value through Execution Excellence





Portfolio

Technology

Unlock Customer Value with Proprietary Technology

Innovation Built on Advantaged Germplasm to Drive Productivity for Farmers and Growth for Corteva

- Strong, diverse, and advanced
 breeding engine to expand genetic potential
- Powerful trait technologies to protect and enhance yield potential
- Customized agronomic solutions and product recommendations

GROWTH SPOTLIGHT | CORN TRIPLES SEGMENT¹

Value for Farmers



- Leading insect traits to meet needs now and in the future
- Enlist[®] Weed Control System provides flexibility and ease of use to farmers across our product portfolio
- NextGen trait launches over next decade with strong pipeline

Value for Corteva

- **Driving value-based pricing** through grower value proposition, trait launches, and genetic rate of gain
- **Increasing volume** through regional growth, share gains, and licensing
- **Expanding margins** by reducing costs, improving producibility, and transitioning to net licensor

Gained Double-Digit Market Share in the Corn Triples Segment Since 2016 and Are Now the Market Leader



Enable a Differentiated Customer Experience through Industry-Leading Brand Portfolio

Comprehensive Route-to-Market based on Customer Segmentation and Buying Preferences



Focused Deployment Based on Local Market Needs




¹ The transgenic soybean event in Enlist E3[®] and Conkesta E3[®] soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies L.L.C.



Proprietary Industry-leading Execution Technology Portfolio Excellence Spotlight: Enabling Greater Market Share through Our Complementary Industry-Leading Brands



Proprietary Industry-leading Execution Technology Portfolio Excellence



Delivering Greater Customer Success through Multiple Channels



Driving Long-Term Value through Execution Excellence

Proprietary Industry-leading Execution Technology Portfolio Excellence

Where We Are Today

Continued Genetic Improvement

• Drives continued business success

Strong Portfolio of Market-Leading Brands

 Enlist E3[®] soybeans¹ on ~65% of U.S. soybean acres

Go-to-Market Excellence

- Deliver products efficiently and reliably
- Optimize route-to-market
- Grow strong farmer relationships

Value-Based Pricing Management

- Optimize price and volume mix
- Pursue royalty neutrality

Near-Term Opportunities

New Product Development and Brand Expansion

- Discover and develop through innovation
- Incorporate proprietary technology and build on growing expertise in gene editing, germplasm, and biotechnology
- Grow Conkesta E3[®] soybeans¹ and PowerCore[®] Enlist[®] corn

End of Decade Opportunities

Build on Branded Business to Unlock Next Wave of Growth

- Launch NextGen corn and soybean traits
- Grow through licensees and multipliers globally (e.g., Brazil soybean market)
- Growth driven by second-generation biofuels

Out-Licensing Strategy that Provides Independent Seed Companies with Tools to Meet Growers' Needs

Proven Performance through Strong Execution and Relentless Focus on Delivering Value



\$4B+

Out-Licensing

Addressable

Market²

Key Takeaways

01

02

03



Leading the corn and soybean markets globally with a clear profitable growth strategy

Innovating for the future to drive product excellence, productivity, and value for farmers Delivering a differentiated customer experience with a focused brand strategy across advantaged routes-to-market

Expanding EBITDA margins through proprietary technology, industry-leading brands, and execution excellence



Crop Protection Overview Well-Positioned for Long-Term Profitable Growth



Robert King | EVP, Crop Protection Business Unit

Key Messages



Delivering industry-leading performance despite recent market challenges



Investing in innovation and growth opportunities to improve portfolio position and penetration in core geographies and crops



Accelerating farmer-centric strategy focused on differentiated solution selling across the full Corteva portfolio



Driving significant cost actions and **improving operating leverage** to deliver financial performance and competitiveness





Crop Protection Snapshot

Financial Performance




Significant Accomplishments Since 2022 Investor Day

- Executed portfolio simplification strategic exit of ~\$500M of low margin products
- Invested in industry-leading biologicals platform, enabling market and technology leadership
- Increased portfolio differentiation¹ to ~65% from ~55% in 2022
- ✓ Significantly increased R&D investment by ~15% with focus on launching innovative solutions
- Reduced COGS through productivity and continuous improvement actions




¹ Differentiated products include (1) active ingredients and biological products patented in major markets, (2) highly
 differentiated actives not encountering generic competition due to trade-secrets, manufacturing or technical barriers to entry
 and (3) products (inclusive of biologicals) providing market leading performance attributes that are protected by trade-secret or unique formulation patents.

Region and Portfolio Mix (% of 2024E Revenue)



Above Peer Average Performance Built on Portfolio Enhancements and Operational Discipline




Continuing to Strengthen and Outperform through the Cycle



applied by peers may not be directly comparable.

Source: Peer revenue / margin data based on combination of externally published information / market research (if available) and internal estimates and analysis. EBITDA margin performance estimated through year-end 2023 using 2020 as a base, if applicable. ¹ Operating EBITDA margin is a non-GAAP measure. See slide 5 for further discussion and reconciliations at the end of this presentation. Operating EBITDA margin definitions as

Strong Market Positions in Growing Addressable Market



Total Crop Protection Market Long-Term Growth




Source: Corteva Internal Analysis
 ¹ Addressable market excludes glyphosate, Russia and Belarus.
 ² Includes fungicides, insecticides, and selective and non-selective herbicides.
 ³ Historical Seed Applied Technology and Biologicals data not available prior to 2021.

Long-Term Strategy to Drive Differentiated Growth



Delivering Differentiated, Farmer-Centric Solutions Across High-Value Market Opportunities



 New Products expected to deliver ~\$550M in incremental top-line growth by 2027

Farmer-Centric

Approach

Investments Improvements

- Significant improvements in overall Differentiation² mix, increasing % of portfolio from ~55% in 2022 to ~65% for 2024E
- Differentiation supports value capture, average margin differential ~10-15 percentage points higher compared to overall CP portfolio average

Innovation Enables Farmer Productivity and Value Capture



¹ Pending applicable regulatory approvals.
² Differentiated products include (1) active ingredients and biological products patented in major markets, (2) highly differentiated actives not encountering generic competition due to trade-secrets, manufacturing or technical barriers to entry and (3) products (inclusive of biologicals) providing market leading performance attributes that are protected by trade-secret or unique formulation patents.

Capturing Opportunity in Biologicals to Further Differentiate and Grow

Biologicals | Where We Are Today

Market-leading,
global position~\$500M in
revenue (2024E)Margin above Crop
Protection portfolio
averageProprietary demand-
creation platformTailored route-to-
market approach
across businesses

Future Opportunity | Market Expected to Grow 6-8% Annually by 2035

- Maintain leadership positions in Brazil and Argentina
- **Expand existing offering** in U.S., Europe and APAC leveraging Corteva market positions
- **Develop a robust biocontrol pipeline** that complements our Crop Protection portfolio

- Pursue acquisitions and investments that leverage commercial platform
- Drive focused R&D leveraging our unique natural product and trait discovery platforms
- Integrate back-office processes and systems to drive further margin expansion








2024 INVESTOR DAY 75

Driving EBITDA Growth through Incremental Cost Actions

Incremental Cost Actions

- **Initial Focus:** *footprint rationalization*, including exit of Pittsburg, CA manufacturing facility and other assets
- **Next phase:** continued productivity initiatives including *supply chain efficiencies, manufacturing optimization* efforts, and *competitive sourcing*
- Opportunity:
 - Additional ~\$200M in cost of goods improvement in 2025 through 2027
 - ~\$300M total run-rate EBITDA savings from operational improvements

Cost Actions - Incremental EBITDA Improvement



Expect to Deliver Significant Value by 2027+ through Cost Actions and Productivity Initiatives



Investments

Improvement

Approach



01 02 03 04)4
-------------	----

Delivering industryleading performance despite recent market challenges **Investing in innovation and growth opportunities** to improve portfolio position and penetration in core geographies and crops Accelerating farmercentric strategy focused on differentiated solution selling across the full

Corteva portfolio

Driving significant cost actions and improving operating leverage to deliver financial performance and competitiveness



Positioned for Success Panel Discussion

MODERATOR

Dave Anderson | Special Advisor to the CEO

PANELIST Tim Glenn | EVP, Seed Business Unit

PANELIST Robert King | EVP, Crop Protection Business Unit

Financial Framework



David Johnson | EVP, Chief Financial Officer



Key Messages



Balanced and diversified portfolio with a leading market position



Focus on cost improvement with track record of delivering significant savings from self-help actions



Sales and operating EBITDA margin expansion driven by price for value strategy and growth platforms




Disciplined capital allocation strategy supported by strong balance sheet and cash flow generation





What We Have Delivered Since 2020




Track Record of Delivering Sales and Operating EBITDA Growth

¹ Operating EBITDA, Operating EBITDA margin, Operating EPS, Free Cash Flow, and Free Cash Flow conversion are non-GAAP measures. See slide 5 for further discussion and reconciliations




Setting the Stage: 2024E Net Sales by Business Unit and Region







2024 – 2027 Financial Outlook



Market Assumptions 2025 – 2027

Seed planted area mostly flat versus 2025 outlook

Crop commodity prices remain relatively stable versus current

On-farm demand remains steady

Crop Protection market flat-to-up LSD 2025-2027


Constant currency versus 2025 outlook rates



Balanced Market Assumptions Support EBITDA Growth 2025 – 2027



Revenue Growth Outlook



Key Assumptions

LSD Seed price and mix from new technology

~80% increase in Seed royalty income vs. 2024

Crop Protection price down LSD


~30% growth in Crop Protection new products

Double-digit CAGR Biological volume 2024 – 2027

Low-Single Digit Growth Through 2027 Driven by Demand for Proprietary Products



¹ Seed base growth represents organic growth excluding royalty income.
 ² Crop Protection base growth represents organic growth excluding new products and Biologicals. It is inclusive of cannibalization of new products.



Growing royalty income with **Conkesta E3**[®] soybeans and **PowerCore**[®] **Enlist**[®] corn

~65% of U.S. soybean acres on Enlist E3¹ driving improvement from 2020 – 2024

100 licensees in U.S. Seed market


NextGen corn and soybean traits to drive value into next decade

On Track to be Royalty Neutral by 2028




¹ The transgenic soybean event in Enlist E3[®] soybeans and Conkesta E3[®] soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies L.L.C.

Cost of Sale Improvement since Year-End 2024



~\$700M of Net Savings Driven by Productivity and Deflation over 3 Years






Delivering \$1 Billion of Operating EBITDA Growth vs 2024E



¹ Operating EBITDA and Operating EBITDA margin are non-GAAP measures. See slide 5 for further discussion and reconciliations at the end of this presentation. ² Base business represents Seed and Crop Protection organic growth excluding impacts from Seed net royalty expense, Crop Protection new products, and Biologicals.

Capital Allocation Strategy

Sources and Uses of Cash 2025 – 2027



Summary Highlights

- Cumulative \$5.6 6.6B Free Cash Flow¹
- Targeting FCF / EBITDA¹ 45-50%
- Commitment to investing in R&D at ~8% of sales
- M&A includes investment in innovation through Corteva Catalyst
- Sustainable and growing dividend
- ~\$4.5B expected to be returned to shareholders

Strong Cash Generation and Disciplined Deployment



M&A and Collaborations to Complement Organic Growth

A Component of a Disciplined and Balanced Capital Allocation Strategy



Highly Disciplined and Consistent Approach to M&A



Checklist for Performance through 2027





Closing Remarks



Chuck Magro | Chief Executive Officer



Why Invest in Corteva?

01

02

03

Strong competitive advantages and deep proprietary expertise, to address one of the world's most essential needs **Proven value creator**, with track record of improving profitability and returning capital to shareholders

Significant growth potential,

driven by product innovation and proven ability to capture share



Appendix

Non-GAAP to GAAP Reconciliations





Corteva, Inc. Non-GAAP Calculation of Corteva Operating EBITDA

			Twelve	Months En	ded Decer	nber 31,		
	20	23	20			21	20	20
In millions	As Reported	Margin %	As Reported	Margin %	As Reported	Margin %	As Reported	Margin %
Income (loss) from continuing operations after income taxes (GAAP)	\$ 941	5.5 %	\$ 1,216	7.0 %	-	11.6 %	\$ 756	5.3 %
Provision for (benefit from) income taxes on continuing operations	152	0.9 %	210	1.2 %	524	3.3 %	(81)	(0.6)%
Income (loss) from continuing operations before income taxes (GAAP)	\$ 1,093	6.3 %	\$ 1,426	8.2 %	\$ 2,346	15.0 %	\$ 675	4.7 %
+ Depreciation and amortization	1,211	7.0 %	1,223	7.0 %	1,243	7.9 %	1,177	8.3 %
- Interest income	(283)	(1.6)%	(124)	(0.7)%	(77)	(0.5)%	(56)	(0.4)%
+ Interest expense	233	1.4 %	79	0.5 %	30	0.2 %	45	0.3 %
+ / - Exchange (gains) losses	397	2.3 %	229	1.3 %	54	0.3 %	174	1.2 %
+ / - Non-operating (benefits) costs	151	0.9 %	(111)	(0.6)%	(1,256)	(8.0)%	(316)	(2.2)%
+ / - Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	_	— %	_	— %		— %		
+ / - Significant items (benefit) charge	579	3.4 %	502	2.9 %	236	1.5 %	388	2.7 %
Corteva Operating EBITDA / EBITDA Margin (Non-GAAP) ^{2,3}	\$ 3,381	19.6 %	\$ 3,224	18.5 %	\$ 2,576	16.5 %	\$ 2,087	14.7 %

1. Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. There were no unrealized mark-to-market gains or losses for the year ended December 31, 2020.

2. Corteva Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.

3. The EBITDA margin percentages are determined by dividing amounts in the table above for the for the twelve months ended December 31, 2023, 2022, 2021 and 2020 by net sales of \$17,226 million, \$17,455 million, \$15,655 million and \$14,217 million, respectively. Margin percentages may not foot, due to rounding.

Corteva, Inc. Segment Information

Net sales by segment				
	Twelve	e Months Er	nded Decem	ber 31,
In millions	2023	2022	2021	2020
Seed	\$ 9,472	\$ 8,979	\$ 8,402	\$ 7,756
Crop Protection	7,754	8,476	7,253	6,461
Total net sales	\$ 17,226	\$ 17,455	\$ 15,655	\$ 14,217
Net Margin (GAAP)				
	Twelve	• Months Fr	nded Decem	ber 31
\$ In millions	2023	2022	2021	2020
Income (loss) from continuing operations after income taxes	\$ 941	\$ 1,216	\$ 1,822	\$ 756
Net Margin (GAAP) ¹	5.5 %			
1. Net Margin is defined as income (loss) from continuing operations after income taxes, as a percentage of net sales.				
Corteva Operating EBITDA				
		-	nded Decem	,
In millions	2023	2022	2021	2020
Seed	\$ 2,117	\$ 1,656	\$ 1,512	\$ 1,208
Crop Protection	1,374	1,684	1,202	1,004
Corporate Expenses Corteva Operating EBITDA (Non-GAAP) ²	(110) \$ 3,381	(116) \$ 3,224	(138) \$ 2,576	(125) \$ 2,087
Conteva Operating EBITDA (Non-GAAP)	৯ ১,১০।	ə 3,224	\$ 2,370	φ 2,007
2. Corteva Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depre exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do significant items. Non-operating benefits (costs) consists of non-operating pension and OPEB credits (costs), tax indemnification adjustments, and legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the term and/or DuPont that are recorded by the company as pre-tax income or expense.	not qualify for environmental	r hedge account remediation and	nting, excluding	the impact of associated with
Operating EBITDA margin				
	Twelve	e Months Er	nded Decem	ber 31,
	2023	2022	2021	2020
Seed	22.4 %			
Crop Protection	17.7 %			
Total Operating EBITDA margin (Non-GAAP) ^{3,4}	19.6 %	18.5 %	16.5 %	14.7 %
3. Operating EBITDA margin is Operating EBITDA as a percentage of net sales.				
4. Operating EBITDA margin %s for Corporate are not presented separately above as they are not meaningful; however, the results are included in the	e Total margin %	%s above.		

Corteva, Inc. Segment Information

Corteva significant items (Pre-tax)

		Twelve	e Months Er	nded Decem	ber 31,
n millions		2023	2022	2021	2020
Seed					
Restructuring and asset related charges - net	\$	(86)	\$ (228)	\$ (152)	\$ (1
Inventory write-offs		(7)	(33)) —	
Seed sale associated with Russia Exit		18	3		
Gain (loss) on sale of business, assets and equity investments		4	(5)) —	
AltEn facility remediation charges		(10)	(33)	—	
Settlement costs associated with Russia Exit		_	(8)	—	
Employee Retention Credit			6	37	
Contract termination			_	(30)	
Equity securities mark-to-market gain (loss)			_	47	
Total Seed	\$	(81)	\$ (298)	\$ (98)	\$ (1
Crop Protection					
Restructuring and asset related charges - net	\$	(228)	\$ (37)	\$ (59)	\$ (1
Estimated settlement expense		(204)	(87)	—	
Spare parts write-off		(12)			
Gain (loss) on sale of business, assets and equity investments		10	15		(
Acquisition-related costs		(45)			
Employee Retention Credit		3	3	23	
Contract termination		_		(24)	
Total Crop Protection	\$	(476)	\$ (106)	\$ (60)	\$ (1
Corporate					
Restructuring and asset-related charges - net	\$	(22)	\$ (98)	\$ (78)	\$ (
Total Corporate	\$	(22)	\$ (98)	\$ (78)	\$ (
Total pre-tax significant items by segment	\$	(579)	\$ (502)	\$ (236)	\$ (3
Total tax (provision) benefit impact of significant items ¹		131	102	51	
Tax only significant items benefit (charge)		45	133	9	1
Fotal significant items benefit (charge), after tax ²	\$	(403)		\$ (176)	

1. Unless specifically addressed above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

2. Additional detail related to these significant items can be found on the Company's investor relations page, https://investors.corteva.com/financial-information/quarterly-earnings-reports.

	Г	Thre	e Mo	onths En	ded D	ecembe	er 31	,
		2023	2022		2	021		2020
	\$	(millions)	\$ (millions)				\$ (r	nillions)
Income (loss) from continuing operations attributable to Corteva common stockholders (GAAP)	\$	929	\$	1,205	\$	1,812	\$	736
Less: Non-operating benefits (costs), after tax ¹		(111)		80		955		237
Less: Amortization of intangibles (existing as of Separation), after tax		(471)		(542)		(562))	(518)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax ²		—		—		—		
Less: Significant items benefit (charge), after tax		(403)		(267)		(176)	,	(110)
	\$	1,914	\$	1,934	\$	1,595	\$	1,127
Operating Earnings (Loss) (Non-GAAP) ³	Φ	1,014						
Operating Earnings (Loss) (Non-GAAP) ³	1							
Operating Earnings (Loss) (Non-GAAP) ³	•		ve N	lonths Er	nded [Decemb	per 3	1,
Operating Earnings (Loss) (Non-GAAP) ³	φ 	Twelv 2023		2022	2	021		2020
Operating Earnings (Loss) (Non-GAAP) ³		Twel			2 E			,
Operating Earnings (Loss) (Non-GAAP) ³	\$	Twelv 2023 EPS	((2022 EPS	2 E (dil	021 EPS	(d	2020 EPS
Earnings (loss) per share of common stock from continuing operations attributable to Corteva	\$	Twelv 2023 EPS (diluted)	((\$	2022 EPS diluted)	2 E (dil \$	021 EPS luted)	(d \$	2020 EPS iluted)
Earnings (loss) per share of common stock from continuing operations attributable to Corteva common stockholders - diluted (GAAP)	\$	Twelv 2023 EPS (diluted) 1.30	((\$	2022 EPS diluted) 1.66	2 E (dil \$	021 EPS luted) 2.44	(d \$	2020 EPS iluted) 0.98
Earnings (loss) per share of common stock from continuing operations attributable to Corteva common stockholders - diluted (GAAP) Less: Non-operating benefits (costs), after tax ¹	\$	Twelv 2023 EPS (diluted) 1.30 (0.16)	((\$	2022 EPS diluted) 1.66 0.11	2 E (dil \$	021 EPS luted) 2.44 1.29	(d \$	2020 EPS iluted) 0.98 0.32
Earnings (loss) per share of common stock from continuing operations attributable to Corteva common stockholders - diluted (GAAP) Less: Non-operating benefits (costs), after tax ¹ Less: Amortization of intangibles (existing as of Separation), after tax	\$	Twelv 2023 EPS (diluted) 1.30 (0.16)	((\$	2022 EPS diluted) 1.66 0.11	2 E (dil \$	021 EPS luted) 2.44 1.29	(d \$	2020 EPS iluted) 0.98 0.32

1. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense.

2. Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. There were no unrealized mark-to-market gains or losses for the year ended December 31, 2020.

3. Operating earnings (loss) is defined as income (loss) from continuing operations attributable to Corteva excluding the after-tax impact of significant items, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-tomarket activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of intangible assets (existing as of Separation) is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-tomarket activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

4. Operating earnings (loss) per share is defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of nonoperating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting.

Corteva, Inc. Non-GAAP Calculation of Free Cash Flow and Free Cash Flow Conversion

				Twelve Mo	nth	ns Ended De	ce	mber 31,		
In millions		2024E Midpoint)	2023			2022		2021		2020
Cash provided by (used for) operating activities - continuing operations (GAAP)	\$	2,350	\$	1,809	\$	912	\$	2,727	\$	2,064
Less: Capital expenditures		(600)		(595)		(605)		(573)		(475
Free Cash Flow (Non-GAAP) ²	\$	1,750	\$	1,214	\$	307	\$	2,154	\$	1,589
Corteva Operating EBITDA (Non-GAAP) ³	\$	3,400	\$	3,381	\$	3,224	\$	2,576	\$	2,087
Free Cash Flow Conversion (Non-GAAP) ⁴				36%		10%		84%		76%
			T۱	welve Month	ns E	Ended Decer	nb	er 31, 2024 ¹		
In millions				Low End				High	En	d
Cash provided by (used for) operating activities - continuing operations (GAAP)	\$					2,100	\$			2,600
Less: Capital expenditures						(600)				(600
Free Cash Flow (Non-GAAP) ²	\$		_		_	1,500	\$			2,000
1. This represents the reconciliation of the Company's range provided for its forward-looking non-GAAP financi	al me	asure relating to	o Fre	e Cash Flow.						
2. Free cash flow is defined as cash provided by (used for) operating activities - continuing operations, less cap	ital e	kpenditures.								
3. Refer to the "Non-GAAP Calculation of Corteva Operating EBITDA" reconciliation for further discussion on C	perat	ing EBITDA.								
4 Free Cash Flow Conversion represents Free Cash Flow divided by Operating ERITDA										

4. Free Cash Flow Conversion represents Free Cash Flow divided by Operating EBITDA.

Appendix

Presenter Bios





Chuck Magro | Chief Executive Officer

Chuck Magro is the Chief Executive Officer of Corteva Agriscience.

Prior to joining Corteva on November 1, 2021, he served as President and CEO of Nutrien from the company's launch in 2018 until April 2021. From 2014 to 2018, Magro served as President and CEO of Agrium, which merged with Potash Corporation of Saskatchewan to create Nutrien.

As President and CEO of Nutrien, Magro led more than 27,000 employees to achieve best-in-class engagement, top safety performance and exceptional business results. He also led the company through numerous M&A transactions, expanding globally and restructuring the industry. Prior to this role, he held a variety of other key leadership positions with the company, including Chief Operating Officer, Chief Risk Officer, Executive Vice President of Corporate Development, and Vice President of Manufacturing. He joined Agrium in 2009 following a productive career with NOVA Chemicals.

From 2018 to 2022, Magro served on the Canadian Pension Plan Investment Board. Previously, he served as Vice Chairman of the International Fertilizer Association and past Chair and Board Member of The Fertilizer Institute. He also served as a Board Steward for the World Economic Forum's Food Systems Initiative, providing strategic leadership to build inclusive, sustainable, efficient, and healthy global food systems, as well as on the Boards of the International Plant Nutrition Institute, Nutrients for Life Foundation, the Business Council of Canada, and the Business Council of Alberta. Magro currently serves on the Boards of CropLife International, Business Roundtable, Ingredion, and the Central Indiana Corporate Partnership. He is also a member of the University of Waterloo Dean's Advisory Council.

Magro holds a Bachelors of Applied Science (Chemical Engineering) degree from the University of Waterloo and an MBA from the University of Windsor.





Brook Cunningham SVP, Chief Strategy Officer

Brook Cunningham is Senior Vice President, Chief Strategy Officer of Corteva Agriscience, a role she assumed in December 2022.

Cunningham is responsible for leading enterprise strategy, mergers and acquisitions, economic and competitive intelligence, sustainability strategy and strategic enablement. She also oversees Corteva's investment steering committee.

Prior to joining Corteva, Cunningham served in the investment banking division of Lazard, most recently as Managing Director and Head of Global Agribusiness and Nutrition. She joined Lazard in New York in 2010, later moving to Chicago in 2012 where she served in a series of progressive leadership roles in the company's Midwest U.S. business and founded the Global Agribusiness and Nutrition practice.

At Lazard, Cunningham advised companies across industries on matters involving corporate strategy, mergers and acquisitions, business separations, strategic investments, corporate finance, capital formation and shareholder engagement. Cunningham was also Co-head of Lazard's Americas Women in Banking Network.

Previously, Cunningham served in the mergers and acquisitions group at Lehman Brothers and, subsequently, Barclays Capital in New York from 2007 to 2010. During her early career, she served in a series of progressive roles at Marsh & McLennan, where she advised corporate and university clients on risk management issues.

Cunningham holds a Master of Business Administration degree from the Stephen M. Ross School of Business at the University of Michigan and a Bachelor of Arts degree in Economics from the University of Michigan.





Sam Eathington | EVP, Chief Technology and Digital Officer

Sam Eathington, Ph.D., is Executive Vice President, Chief Technology and Digital Officer of Corteva Agriscience.

Eathington is responsible for leading the company's global Research and Development organization, including its industryleading Seed and Crop Protection pipeline, and for driving digital innovation companywide. He assumed his current role after joining the company in 2020 as Senior Vice President and Chief Technology Officer.

A recognized leader in agricultural innovation, Eathington served as Chief Science Officer of The Climate Corporation (part of Bayer Crop Science) for four years before joining Corteva Agriscience. Earlier, he spent nearly two decades with Monsanto, holding multiple progressive roles in quantitative traits and molecular breeding and serving as Vice President, Global Plant Breeding.

Eathington holds a Bachelor of Science in agronomy, a Master of Science in soybean breeding and genetics and a Ph.D. in quantitative genetics and maize breeding, all from the University of Illinois, Urbana-Champaign.





Tim Glenn | EVP, Seed Business Unit

Tim Glenn is Executive Vice President, Seed Business Unit of Corteva Agriscience, a role he assumed in April 2022.

Glenn is a highly experienced agriculture industry leader, with global expertise across seeds, crop protection, sales, marketing, integrated operations, and commercial effectiveness. He has served the company and its predecessor organizations for more than 30 years.

Most recently, he was Executive Vice President, Chief Commercial Officer for Corteva Agriscience, with responsibility for the company's global commercial organization since 2018. He had previously served as Vice President of the Global Seed Business Platform for Corteva, leading the establishment of the company's seed business strategy.

Glenn initially joined Pioneer Hi-Bred in 1991 and held a variety of marketing roles working in seed markets around the world. In 1997, he joined Dow AgroSciences as Corn Product Manager, Mycogen Seeds, and served in key sales and business leadership roles in the Crop Protection and Seeds businesses of Dow AgroSciences.

Glenn rejoined Pioneer in 2006 as Director of Marketing, North America and subsequently held other leadership positions including Regional Business Director of Latin America and Canada and Vice President of Integrated Operations and Commercial Effectiveness for the DuPont Pioneer business. In 2015, he was appointed President of DuPont Crop Protection.

Glenn holds a Bachelor of Science from Iowa State University, College of Agriculture, and an MBA from Santa Clara University Leavey School of Business. He is a member of the Iowa Business Council, and previously served on the Board of Directors for the Brazil-U.S. Business Council and the Food Bank of Iowa.



Robert King | EVP, Crop Protection Business Unit

Robert King is Executive Vice President, Crop Protection Business Unit at Corteva Agriscience, a role he assumed in April 2022.

King is a highly experienced specialty chemicals and agriculture industry executive with experience leading teams in the U.S., Canada, China, and the U.K. and a long track record of improving operational capabilities and driving top- and bottom-line growth.

Prior to joining Corteva, King served most recently as Senior Vice President and Chief Integrated Supply Chain Officer at Nouryon, a specialty chemicals company, where he spearheaded the global and cross-business integration of the company's supply chain.

Before his time at Nouryon, he served as Vice President of Global Operations for PPG's industrial segment and Vice President of Global Supply Chain for Nutrien, where he worked for five years and was appointed to lead the centralization of the company's supply chain. Before this role, he served as a Regional Manager at Nutrien and as the Vice President of Nitrogen Operations and Services at Agrium in Canada before the company became Nutrien in 2018.

King started his career at Celanese, where he worked for nearly two decades and held management roles in the U.S., China, and the U.K.

King holds a Bachelor of Science in Chemical Engineering from Texas Tech University, an MBA from Texas Woman's University, and is also a Master Black Belt in Lean Six Sigma. He is a former Board Member and Chair of the Texas Tech Chemical Engineering External Advisory Board and has volunteered with several professional mentorship organizations.



Dave Anderson Special Advisor to the Chief Executive Officer

Dave Anderson is Special Advisor to Corteva Agriscience's Chief Executive Officer.

Anderson assumed the role of Special Advisor after serving as the company's EVP, CFO since April 2021. His current responsibilities include overseeing strategic projects and the IT function, while ensuring a seamless transition with Corteva's incoming CFO.

Having served as CFO of diverse global companies across a range of industries, Anderson has developed a strong track record of driving shareholder returns and value creation. He also has significant experience advising on and executing strategies to optimize productivity and strengthen portfolios, while improving balance sheets and enhancing corporate governance.

Prior to Corteva, Anderson was Interim CFO at Criteo S.A., which he joined after serving as CFO and Chief Operating Officer at Nielsen Holdings plc. He previously was CFO for Alexion Pharmaceuticals, Honeywell, ITT, Inc., Newport News Shipbuilding Inc., and RJR Nabisco, Inc.

Anderson holds a Bachelor of Science in Economics from Indiana University and earned his Master of Business Administration at the University of Chicago's Booth School. He is a Board member of American Electric Power. He has been recognized by Institutional Investor magazine as one America's Top CFOs in their annual survey of investors and sell-side analysts.





David Johnson EVP, Chief Financial Officer

David Johnson is Executive Vice President, Chief Financial Officer for Corteva Agriscience.

Johnson is an experienced Chief Financial Officer, with a proven track record of consistently driving results, operational efficiency and financial discipline at large, global organizations. He has more than three decades of experience in strategic and financial planning, risk assessment, mergers and acquisitions, global tax strategies, international operations, and internal controls.

Prior to joining Corteva, Johnson was Vice President, Chief Financial Officer and Chief Accounting Officer at Atkore, a publicly traded company and leader in electrical, safety, and infrastructure solutions. In this role, he was responsible for all financial and information technologies activities and during his six years at the company, the business transformed through acquisitions and organic growth investments into a leading electrical products company.

Johnson previously spent 29 years at Eaton Corporation, a leading power management company dedicated to improving the quality of life and protecting the environment for people everywhere, most recently serving as Vice President, Finance and Operations for its Electrical Sector business.

Johnson holds a Bachelor of Science in Finance with a minor in Accounting from Indiana University of Pennsylvania and a Master of Business Administration from Duquesne University.

